Oncology-New York最新文献

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease. 诊断特异性分级预后评估在轻脑膜疾病预测中的应用。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-05-12 DOI: 10.46883/2025.25921040

Meghana Kesireddy, Rosalyn Marar, Kaeli Samson, Nicole Shonka

{"title":"Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease.","authors":"Meghana Kesireddy, Rosalyn Marar, Kaeli Samson, Nicole Shonka","doi":"10.46883/2025.25921040","DOIUrl":"10.46883/2025.25921040","url":null,"abstract":"Leptomeningeal disease (LMD) is the spread of cancer cells to the arachnoid mater, pia mater, and cerebrospinal fluid. It occurs in 5% to 10% of solid organ cancers, with higher rates in breast, lung, and melanoma cancers. The prognosis for patients with LMD remains poor, with a median survival of 1.5 months without treatment and 2 to 3 months with treatment, despite advances in cancer treatment. This retrospective study included 64 patients with LMD with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years. Patient characteristics, treatment, and overall survival (OS) data were collected. Statistical analyses included descriptive statistics, log-rank tests, and Cox proportional hazards regression models. The median OS for the 64 patients with LMD was 2.6 months, with no statistically significant differences among cancer types. Though not statistically significant, those with higher DS-GPA scores trended toward longer survival in breast and lung cancer cohorts. Patients with LMD on imaging confined to 1 location (cerebrum, cerebellum, spine, or cranial nerves) and receiving systemic chemotherapy alone also had longer survival. The DS-GPA tool is promising for LMD prognostication and may be strengthened by incorporating imaging and chemotherapy characteristics. Larger, multicenter studies are needed to validate its prognostic utility. Keywords: Leptomeningeal disease, diagnosis-specific graded prognostic assessment, prognosis, overall survival, breast cancer, lung cancer.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 4","pages":"141-147"},"PeriodicalIF":1.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System. 罕见的原发性中枢神经系统alk阳性间变性大细胞淋巴瘤。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-05-12 DOI: 10.46883/2025.25921039

Nathalie Soler, Kelly Paz Amador, Alexandra Perez, Camila Solis, Alexander Reyes, Jorge Garcia, Maria Paula Gonzalez Zambrano, Edgar Fabián Manrique Hernández

引用次数: 0

Synovial Fluid in Checkpoint Inhibitor-Induced Inflammatory Arthritis. 滑膜液在检查点抑制剂诱导的炎性关节炎中的作用。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-05-12 DOI: 10.46883/2025.25921041

Mary Katherine L Anderson, James P Fagerland, Samantha Kohn, Amy C Cannella, Benjamin A Teply Md

{"title":"Synovial Fluid in Checkpoint Inhibitor-Induced Inflammatory Arthritis.","authors":"Mary Katherine L Anderson, James P Fagerland, Samantha Kohn, Amy C Cannella, Benjamin A Teply Md","doi":"10.46883/2025.25921041","DOIUrl":"10.46883/2025.25921041","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of advanced malignancies, but they can cause a wide range of adverse effects, including inflammatory arthritis. Severe ICI-induced inflammatory arthritis (ICI-IA) is rare, and its distinguishing clinical features are not defined. We present a patient with metastatic urothelial carcinoma who developed severe, polyarticular inflammatory arthritis while being treated with an ICI. Arthrocentesis of native and prosthetic joints revealed a significantly elevated white blood cell (WBC) count with a neutrophil predominance. Antibiotics were discontinued when the extensive infectious workup remained negative, and the patient was diagnosed with ICI-IA. This presentation of ICI-IA had overlapping features with septic arthritis, resulting in high diagnostic uncertainty. We comprehensively reviewed all published literature on the clinical features of severe ICI-IA. In the literature, synovial fluid findings revealed variable WBC counts but consistently have a neutrophil predominance. Although severe cases are rare, 9 previously reported cases shared similarities, including polyarticular presentation, elevated inflammatory markers, and absence of other rheumatic disease. Severe ICI-IA appears to have significant clinical overlap with culture-negative septic arthritis. This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered. Keywords: checkpoint inhibitor, inflammatory arthritis, immune-related adverse effects.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 4","pages":"148-152"},"PeriodicalIF":1.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer. 唾液抗氧化剂的生物医学研究进展：探讨其在口腔癌前和癌中的意义。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-04-14 DOI: 10.46883/2025.25921038

Vidya G Doddawad, B M Gurupadayya, Vidya Cs, Shivananda S, Karthikeya Patil, R Sumukh Bharadwaj

{"title":"Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer.","authors":"Vidya G Doddawad, B M Gurupadayya, Vidya Cs, Shivananda S, Karthikeya Patil, R Sumukh Bharadwaj","doi":"10.46883/2025.25921038","DOIUrl":"https://doi.org/10.46883/2025.25921038","url":null,"abstract":"Under normal physiological circumstances, an equilibrium exists between prooxidants and antioxidants in the body. The body generates free radicals as part of its natural cellular metabolism. However, when there is an unevenness or modification in the levels of antioxidants, it gives rise to a state known as oxidative stress. This phenomenon is implicated in numerous pathological conditions. It can potentially harm cells by causing minor injuries to cell membranes, deactivating proteins, damaging DNA, and triggering tissue damage through cell-signaling molecules. Human saliva is a diagnostic fluid that is rich in antioxidant compounds and plays a primary role in the protective mechanism. These antioxidants neutralize the free radicals, including reactive oxygen species and reactive nitrogen species, that are released due to oxidative stress and prevent cell breakdown, tissue damage, and DNA mutations. Whole human saliva may contain numerous antioxidants that are measurable tools to monitor the oral cavity's oxidative processes and help guide the development of new drugs or treatment plans. This article provides extensive information on salivary antioxidants and their role in common oral lesions like inflammatory, premalignant, malignant, and autoimmune diseases.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 3","pages":"111-117"},"PeriodicalIF":1.8,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity. 癌症护理中的人工智能：应对挑战和健康公平。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-04-14 DOI: 10.46883/2025.25921037

Viviana Cortlana Ms, Kennedy Itodo Bs, Yan Leyfman Md, Jenna Ghazal BSc, Vraj JigarKumar Rangrej Mbbs, Adhith Theyver, Chandler H Park Md Facp

{"title":"Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity.","authors":"Viviana Cortlana Ms, Kennedy Itodo Bs, Yan Leyfman Md, Jenna Ghazal BSc, Vraj JigarKumar Rangrej Mbbs, Adhith Theyver, Chandler H Park Md Facp","doi":"10.46883/2025.25921037","DOIUrl":"https://doi.org/10.46883/2025.25921037","url":null,"abstract":"Overdiagnosis in cancer care remains a significant concern, often resulting in unnecessary physical, emotional, and financial burdens on patients. Artificial intelligence (AI) has the potential to address this challenge by enabling more accurate, personalized cancer diagnoses and facilitating tailored treatment plans. Integrating AI with precision medicine can minimize unnecessary treatments and associated adverse effects by optimizing care strategies based on individual patient data. However, the integration of AI in oncology requires rigorous research and validation to ensure its effectiveness across diverse populations and clinical settings. Challenges such as algorithmic bias, data representation, and limited access to technology in resource-constrained settings highlight the need for equitable AI applications in health care. Addressing health equity disparities is critical, as diverse and representative training data sets significantly affects the fairness and efficacy of AI systems. AI also holds promise for advancing cancer care in resource-limited settings by providing cost-effective diagnostic tools, democratizing access to advanced health care technologies, and improving outcomes in low- and middle-income nations. Interdisciplinary and international collaborations between researchers, clinicians, and technologists are crucial to maximizing AI's potential in cancer care. By fostering these partnerships and focusing on the development of accessible, ethical, and patient-centered AI applications, the health care community can revolutionize cancer diagnosis and treatment. The growing role of AI in precision medicine brings hope for equitable, cost-effective, and improved patient outcomes worldwide.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 3","pages":"105-110"},"PeriodicalIF":1.8,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies. 拓展 T 细胞淋巴瘤治疗的视野：关注个性化治疗策略。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-03-03 DOI: 10.46883/2025.25921036

Viviana Cortlana, Jade Gambill, Jenna Ghazal, Kennedy Itodo, Shreevikaa Kannan, Yan Leyfman, Chandler H Park

{"title":"Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies.","authors":"Viviana Cortlana, Jade Gambill, Jenna Ghazal, Kennedy Itodo, Shreevikaa Kannan, Yan Leyfman, Chandler H Park","doi":"10.46883/2025.25921036","DOIUrl":"10.46883/2025.25921036","url":null,"abstract":"T-cell lymphoma, a form of non-Hodgkin lymphoma, presents significant treatment challenges due to its diverse subtypes and aggressive progression. Jasmine Zain, MD, drawing on her expertise in chimeric antigen receptors (CAR) T-cell therapies, is focused on expanding therapeutic options for T-cell lymphomas, particularly peripheral T-cell lymphoma (PTCL). A critical aspect of treatment development involves recognizing that the subtypes of nodal PTCL are defined by specific genetic pathways, which determine their response to different therapies. This insight has led to the development of more personalized, subtype-specific treatment strategies. Current treatment approaches for PTCL typically involve combinations of chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation. The standard first-line therapy, CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone), has relatively low response rates, highlighting the need for more effective alternatives. While stem cell transplantation is beneficial for certain PTCL subtypes, overall outcomes remain inconsistent. Some targeted therapies have shown efficacy in specific subtypes, but many forms of PTCL are still resistant to available treatments, underscoring the need for further research. In cases of relapsed/refractory disease, stem cell transplantation remains the primary treatment option, though it is associated with significant risks and often impacts patients' quality of life. There is a pressing need for new, less toxic therapies. Several targeted drugs are currently in clinical trials, with the goal of improving treatment options for patients with relapsed/refractory PTCL. Ongoing research into the genetic and molecular characteristics of PTCL aims to develop more individualized therapies that are better suited to each patient's specific disease profile, offering hope for improved outcomes in this challenging lymphoma subtype.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 2","pages":"80-84"},"PeriodicalIF":1.8,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in Surgical Management of the Axilla. 腋窝外科治疗的最新进展。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-03-03 DOI: 10.46883/2025.25921035

Anita Mamtani, Andrea V Barrio

{"title":"Updates in Surgical Management of the Axilla.","authors":"Anita Mamtani, Andrea V Barrio","doi":"10.46883/2025.25921035","DOIUrl":"10.46883/2025.25921035","url":null,"abstract":"Over the past 3 decades, axillary management in patients with breast cancer has evolved dramatically. The introduction and increasing use of sentinel lymph node biopsy (SLNB) have revolutionized the surgical approach for many patients with early breast cancer, permitting appropriate axillary staging without compromising prognosis and conferring significantly less morbidity than axillary lymph node dissection (ALND). For patients with clinically node-negative breast cancer and pathologically negative nodes or limited nodal metastases who have up-front surgery followed by radiotherapy, SLNB alone is now the standard of care, as it is for many patients who are clinically node positive and achieve a nodal pathologic complete response to neoadjuvant therapy. Omission of SLNB is also becoming possible for many patients with early-stage hormone receptor-positive/HER2-negative clinically node-negative breast cancer, with a large randomized trial demonstrating noninferiority of omission of axillary surgery to SLNB. Conversely, for those with residual nodal disease after neoadjuvant chemotherapy or those with a clinically positive axilla who have up-front surgery, ALND remains indicated, although clinical trials evaluating de-escalation of axillary surgery in these patient subsets are ongoing. As multidisciplinary treatment paradigms become increasingly nuanced, it is crucial that systemic therapy treatment decisions for patients with early-stage breast cancer be based on the available pathologic nodal status provided by SLNB, without the need for ALND to find additional positive nodes. Here we review recent advances and ongoing controversies in the modern surgical management of the axilla in breast cancer.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 2","pages":"70-75"},"PeriodicalIF":1.8,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Potential for Improved Processes, Outcomes, and Economics of Health Care. 改进卫生保健过程、结果和经济的潜力。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-02-04 DOI: 10.46883/2025.25921034

Nora Janjan Md Mpsa Mba

引用次数: 0

Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research. 边缘地带淋巴瘤研究的见解、知识差距和优先事项。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-02-04 DOI: 10.46883/2025.25921033

Lymphoma Research Foundation Lymphoma Research Foundation

{"title":"Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research.","authors":"Lymphoma Research Foundation Lymphoma Research Foundation","doi":"10.46883/2025.25921033","DOIUrl":"10.46883/2025.25921033","url":null,"abstract":"Marginal zone lymphoma (MZL) is a rare, indolent form of non-Hodgkin lymphoma that arises from B cells in the marginal zone of lymphoid tissues. MZL comprises 3 key subtypes: extranodal, nodal, and splenic MZL. Despite being generally slow growing, MZL presents significant challenges due to its heterogeneous nature, inconsistently defined disease, and the limited efficacy and availability of current treatments. Advancements in targeted therapies and a deeper understanding of the molecular underpinnings of MZL are critical to improving patient outcomes and achieving more durable remissions. At the Lymphoma Research Foundation's 2024 Marginal Zone Lymphoma Virtual Scientific Workshop, researchers gathered to discuss recent developments in both basic scientific and clinical research so that together we can continue to develop our understanding of MZL and improve outcomes for patients. This report, which includes a summary of each presentation, aims to review the findings presented at the workshop. Additionally, it highlights opportunities, reviews questions, and assesses areas for future study to set the stage for treatment advancements in the coming decades.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"1 null","pages":"11-32"},"PeriodicalIF":1.8,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials. 转移性非小细胞肺癌临床试验外治疗的临床试验资格和结果

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-12-03 DOI: 10.46883/2024.25921032

Clayton K Oakley, Amulya Yellala, Sunil Tulpule, Robin High, Apar Kishor Ganti, Alissa S Marr

{"title":"Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials.","authors":"Clayton K Oakley, Amulya Yellala, Sunil Tulpule, Robin High, Apar Kishor Ganti, Alissa S Marr","doi":"10.46883/2024.25921032","DOIUrl":"10.46883/2024.25921032","url":null,"abstract":"Introduction: There are limited data available regarding patient outcomes in those who would have been ineligible to receive therapy based on the original clinical trial eligibility criteria. We decided to conduct a retrospective study to evaluate outcomes based on clinical trial eligibility in patients with metastatic non-small cell lung cancer (NSCLC).Methods: A retrospective chart review of all patients with metastatic NSCLC who received first-line systemic therapy at a single academic institution was performed. Each patient's chart was reviewed to determine if they would have qualified for the phase 3 clinical trial that led to the approval of the specific treatment regimen which they received. Data were analyzed to determine if there was a difference in survival time between those who would have been eligible compared with those who were ineligible for the clinical trial of the treatment regimen administered.Results: There were 170 patients with a diagnosis of metastatic NSCLC who received first-line systemic therapy. Of these, 109 received combined chemotherapy, 25 received immunotherapy, and 36 received targeted therapy. There is a statistically significant difference in the restricted mean survival time between the eligible and ineligible groups in those who received combined chemotherapy (19.9 months vs 13.2 months; P = .03), but not in either the immunotherapy group (22.4 months vs 12.9 months; P = .06) or the targeted therapy group (57.7 months vs 39.0 months; P = .14).Conclusion: These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 12","pages":"462-468"},"PeriodicalIF":1.8,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0